LEIDEN, NETHERLANDS--(Marketwire - January 05, 2012) - OctoPlus N.V. ("OctoPlus" or the
"Company") (Euronext: OCTO) announces today that it has won an expansion of
its drug delivery technology evaluation contract
with an existing client, a top-5 global pharmaceutical company.
OctoPlus has
performed feasibility work for previous compounds of this client in
2009 and
2010 and those studies have been successful. Pre-clinical studies performed
with
the prototype controlled release formulation were also successful.
Under the contract announced today, we will develop a controlled
release
formulation that combines the client's optimized product candidate
with our
proprietary drug delivery technology PolyActive(®). If the
project is
successful, the contract may progress to a full process
development and
manufacturing contract, and a licensing agreement.
About OctoPlus
OctoPlus is a specialty pharmaceutical company focused on the
development and
manufacture of improved injectable pharmaceuticals based on our proprietary
drug
delivery technologies that exhibit fewer side effects, improved
patient
convenience and a better efficacy/safety balance than existing
therapies.
OctoPlus also focuses on the development of long-acting, controlled
release
versions of known protein therapeutics, peptides and small molecules,
including
specialty generics.
The clinically most advanced product incorporating our
technology is
Locteron(®), a controlled release formulation of interferon
alpha for the
treatment of chronic hepatitis C. OctoPlus licensed Locteron
exclusively to
Biolex in October 2008. Locteron is being manufactured for Biolex by
OctoPlus
and has completed Phase IIb clinical studies with superior clinical data
versus
current treatment.
In addition, OctoPlus is a leading European provider of advanced
drug
formulation and clinical scale manufacturing services to the
pharmaceutical and
biotechnology industries, with a focus on difficult-to-formulate
active
pharmaceutical ingredients.
OctoPlus is listed on NYSE Euronext in Amsterdam under the symbol OCTO. For
more
information about OctoPlus, please visit our website www.octoplus.nl.
This document may contain certain forward-looking statements relating
to the
business, financial performance and results of the Company and the
industry in
which it operates. These statements are based on OctoPlus N.V.'s current
plans,
estimates and projections, as well as its expectations of external
conditions
and events. In particular the words "expect", "anticipate",
"predict",
"estimate", "project", "plan", "may", "should", "would", "will",
"intend",
"believe" and similar expressions are intended to identify forward-
looking
statements. We caution investors that a number of important factors,
and the
inherent risks and uncertainties that such statements involve, could
cause
actual results or outcomes to differ materially from those expressed
in any
forward-looking statements. In the event of any inconsistency between an
English
version and a Dutch version of this document, the English version will
prevail
over the Dutch version.
Click here for the press release in PDF format:
http://hugin.info/137076/R/1575105/490516.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
[HUG#1575105]
